natgillin/translations-raw huggingface dataset:
Efficacy was studied in patients with atrial fibrillation after cardiac surgery in ACT II, a phase 3, double-blind, placebo-controlled, parallel group study (ACT II) in 150 patients with sustained atrial fibrillation (3 hours to 72 hours duration) that occurred between 24 hours and 7 days post coronary artery bypass graft and/or valvular surgery.
150 bolnikov z obstojno atrijsko fibrilacijo (trajanje od 3 ure do 72 ur), ki se je pojavila od 24 ur do 7 dni po obvodni operaciji koronarnih arterij in/ali operaciji zaklopk.
Efficacy, as measured by improvements in OS and PFS, was associated with increasing ramucirumab exposure range produced by 8 mg/kg ramucirumab given every 2 weeks and by 10 mg/kg ramucirumab given every 3 weeks.
Učinkovitost, merjena z izboljšanji preživetja in preživetja brez poslabšanja bolezni, je bila povezana s povečanjem obsega izpostavljenosti ramucirumabu, ki ga je omogočil odmerek ramucirumaba 8 mg/kg, dan vsaka 2 tedna, in odmerek ramucirumaba 10 mg/kg, dan vsake 3 tedne.
efficacy, caution is
lumefantrina lahko povzroči
efficacy.
učinkovitost.
Efficib has no or negligible influence on the ability to drive and use machines.
Zdravilo Efficib nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Efficib must not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Zdravila Efficib se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavji 4.3 in 5.2).
Efficib should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 mL/min) (see sections 4.3 and 4.4).
Zdravila Efficib se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro (kreatininski očistek < 60 ml/min) (glejte poglavji 4.3 in 4.4).
Efient 10 mg film-coated tablets Efient 5 mg film-coated tablets Prasugrel
Efient 10 mg filmsko obložene tablete Efient 5 mg filmsko obložene tablete prasugrel
Efient 10 mg film-coated tablets prasugrel
Efient 10 filmsko obložene tablete prasugrel
Efient 10 mg film-coated tablets prasugrel
Efient 10 mg filmsko obložene tablete prasugrel
Efient 10 mg film-coated tablets.
Efient 10 mg filmsko obložene tablete
Efient 10 mg: The tablets are beige and double-arrow shaped, with ”10 MG” debossed on one side and “4759” on the other.
Efient 10 mg: Tablete so bež barve, v obliki dvojne puščice, z vtisnjenim “10 MG” na eni strani in “4759” na drugi strani.
Efient 5 mg film-coated tablets prasugrel
Efient 5 mg filmsko obložene tablete prasugrel
Efient 5 mg film-coated tablets.
Efient 5 mg filmsko obložene tablete
Efient 5 mg: The tablets are yellow and double-arrow-shaped, with “5 MG” debossed on one side and “4760” on the other.
Efient 5 mg: Tablete so rumene barve, v obliki dvojne puščice, z vtisnjenim “5 MG” na eni strani in “4760” na drugi strani.
Efient contains lactose.
Zdravilo Efient vsebuje laktozo.
Efient is unlikely to affect your ability to drive or use machines.
Za zdravilo Efient je malo verjetno, da vpliva na vašo sposobnost upravljanja vozil in strojev.
Efient should be given as a single 60 mg loading dose and then continued at a 5 mg once daily dose.
Zdravilo Efient moramo dati kot enkratni 60 mg polnilni odmerek in nato nadaljevati s 5 mg odmerkom enkrat na dan.
Efient should not be used in children and adolescents below 18 years of age.
Zdravilo Efient se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).
Zdravilo Efient, dano sočasno z acetilsalicilno kislino (ASK), je indicirano za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih z akutnim koronarnim sindromom (t.j. nestabilna angina pektoris, miokardni infarkt brez elevacije ST spojnice [non-ST segment elevation myocardial infarction, UA/NSTEMI] ali miokardni infarkt z elevacijo ST spojnice [ST segment elevation myocardial infarction, STEMI], ki imajo odloženo perkutano koronarno intervencijo (percutaneous coronary intervention, PCI).
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).
Zdravilo Efient, dano sočasno z acetilsalicilno kislino (ASK), je indicirano za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih z akutnim koronarnim sindromom (t.j. nestabilna angina pektoris, miokardni infarkt brez elevacije ST spojnice [non-ST segment elevation myocardial infarction, UA/NSTEMI] ali miokardni infarkt z elevacijo ST spojnice [ST segment elevation myocardial infarction, STEMI], ki imajo primarno ali odloženo perkutano koronarno intervencijo (percutaneous coronary intervention, PCI).
Efient, which contains the active substance prasugrel, belongs to a group of medicines called anti- platelet agents.
Efient, ki vsebuje zdravilno učinkovino prasugrel, spada v skupino zdravil, imenovanih zdravila proti trombocitom.
Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme involved in the production of the hair shaft by the hair follicle.
Eflornitin ireverzibilno inhibira ornitin-dekarboksilazo, encim udeležen pri izgradnji lasnega stebla v lasnem mešičku.
efmoroctocog alfa (recombinant coagulation factor VIII)
efmoroktokog alfa (efmoroctocogum alfa) (rekombinantni koagulacijski faktor VIII)
Efmoroctocog alfa (recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc)) has 1890 amino acids.
Efmoroktokog alfa (rekombinantni humani koagulacijski faktor VIII, fuzijska beljakovina Fc (rFVIIIFc)) ima 1.890 aminokislin.
efmoroctocog alfa recombinant coagulation factor VIII IV
efmoroctocogum alfa rekombinantni koagulacijski faktor VIII i.v.
efmoroctocog alfa recombinant coagulation factor VIII, Fc fusion protein
efmoroctocogum alfa rekombinantni koagulacijski faktor VIII, fuzijska beljakovina Fc
EFS (median)
EFS (mediana)
EFS – Event Free Survival
EFS: preživetje brez dogodka (Event Free Survival)
eftrenonacog alfa recombinant coagulation factor IX IV
eftrenonacogum alfa rekombinantni koagulacijski faktor IX i.v.
eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein
eftrenonakog alfa (eftrenonacogum alfa), rekombinantni koagulacijski faktor XI, fuzijska beljakovina Fc
EFV + IDV + NRTIs
EFV + IDV + NRTI-ji
EFV + NRTIs
EFV + NRTI-ji
EFV = efavirenz; FTC = emtricitabine; TDF = tenofovir disoproxil fumarate; E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive).
EFV = efavirenz; FTC = emtricitabin; TDF = dizoproksiltenofovirat fumarat; E/C/F/TDF = elvitegravir/kobicistat/emtricitabin/dizoproksiltenofovirat fumarat a Okno v 48. tednu je med 294. in 377. dnevom (vključno z njima).
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabine 200 mg in the form of Atripla FDC.
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabin 200 mg v obliki Atripla FDC.
EGFR
Negativna
EGFR
Pozitivna
EGFR activates proteins called RAS.
EGFR aktivira proteine, imenovane RAS.
eGFR change mL/min/1.73 m2: median (range)
Sprememba eGFR ml/min/1,73 m2: mediana (razpon)
eGFR improvement
Izboljšanje eGFR
eGFR improvement ≥ 15 mL/min/1.73m2
Izboljšanje eGFR ≥ 15 ml/min/1,73 m2
eGFR improvement ≥15 mL/min/ 1.73•m2, n (%)
izboljšanje eGFR ≥15 ml/min/ 1,73•m2, n (%)
EGFR mutation status and clinical characteristics
Stanje mutacije EGFR in klinične značilnosti
EGFR mutation testing should be performed prior to initiation of Tarceva therapy in chemo-naïve patients with advanced or metastatic NSCLC.
Pri bolnikih z lokalno napredovalim ali metastatskim nedrobnoceličnim rakom pljuč, ki še niso prejeli kemoterapije, je treba testiranje za določanje mutacij EGFR opraviti pred začetkom zdravljenja z zdravilom Tarceva.
EGFR mutation-
12,7 m
EGFR T790M mutation status should be determined by using a validated test method (see section 4.4).
Stanje mutacije T790M EGFR je treba določiti z validirano testno metodo (glejte poglavje 4.4).
eGFR ≥45 to
Vrednost eGFR ≥ 45 do
eGFR ≥60 to <90 ml/min/1.73 m²
Vrednost eGFR ≥ 60 do < 90 ml/min/1,73 m²
Eggs (chicken): zero days.
Jajca (piščanci): nič dni.
EID50: 50% embryo infective dose - the titre required to infect 50% of the embryos inoculated with the virus.
EID50 - 50-odstotni infektivni odmerek za zarodke: titer virusa, ki povzroči okužbo pri 50 % inokuliranih zarodkov.
EID50: 50% embryo infective dose - the virus titre required to produce infection in 50% of the embryos inoculated.
EID50: 50-odstotni infektivni odmerek za zarodke: titer virusa, ki povzroči okužbo pri 50 % inokuliranih zarodkov.
Eight (0.9%) patients, including 2 of those with QTcF interval prolongation of greater than 500 ms, experienced QTcF increase from baseline exceeding 60 ms.
Pri osmih bolnikih (0,9 %), vključno z dvema od tistih, pri katerih je bilo podaljšanje QTcF večje od 500 ms, je prišlo do podaljšanja QTcF za več kot 60 ms glede na izhodišče.
Eight (19%) patients had a new cytogenetic abnormality reported, including 5 patients who had changes in chromosome 7.
O prisotnosti nove citogenetske nepravilnosti so poročali pri osmih bolnikih (19 %), med katerimi je pri 5 bolnikih prišlo do sprememb na kromosomu 7.
Eight (2%) tenofovir disoproxil 245 mg (as fumarate) treated patients developed the K65R mutation within the first 48 weeks.
Osem (2%) bolnikov, zdravljenih z 245 mg dizoproksiltenofoviratom (v obliki dizoproksiltenofovirijevega fumarata), je razvilo K65R mutacijo v teku prvih 48 tednov.
eight 25 mg tablets twice daily or two 100 mg tablets twice daily or one 200 mg tablet twice daily
osem 25 mg tablet dvakrat na dan ali dve 100 mg tableti dvakrat na dan ali ena 200 mg tableta dvakrat na dan
Eight hundred and twenty-nine patients were randomised (292 FOLFOX-4, 293 Avastin + FOLFOX-4 and 244 Avastin monotherapy).
Randomizirali so 829 bolnikov (zdravljenje po shemi FOLFOX-4 je prejemalo 292 bolnikov, zdravilo Avastin in zdravljenje po shemi FOLFOX-4 293 bolnikov ter zdravilo Avastin kot samostojno zdravljenje 244 bolnikov).
Eight malignancies in the combined golimumab treatment group (n = 230) and none in the placebo treatment group (n = 79) were reported.
Poročali so o osmih malignomih v kombinirani skupini, zdravljeni z golimumabom (n = 230), in nobenem v skupini, ki je prejemala placebo (n = 79).
Eight of these patients had DVT, one with Grade 1, two with Grade 2, four with Grade 3 and one with Grade 4.
Osem od teh bolnikov je imelo globoko vensko trombozo: en 1. stopnje, dva 2. stopnje, štirje 3. stopnje in en 4. stopnje.
Eight patients had HIV that expressed K65R in the tenofovir disoproxil 245 mg (as fumarate) arm, 7 of these occurred during the first 48 weeks of treatment and the last one at week 96.
V skupini z 245 mg dizoproksiltenofoviratom (v obliki dizoproksiltenofovirijevega fumarata) je imelo 8 bolnikov HIV, ki je izražal mutacijo K65R, pri 7 od teh se je ta pojavila v prvih 48 tednih zdravljenja, pri enem pa v 96. tednu.
Eight percent of patients had Grade ≥3 infusion reactions at any time during treatment.
Osem odstotkov bolnikov je imelo kadar koli med zdravljenjem infuzijske reakcije  3. stopnje.
Eight years after vaccination, 85%, 85%, 97% and 40% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 88%, 81%, 100% and 81% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
Osem let po cepljenju je bilo 85 %, 85 %, 97 % oziroma 40 % oseb seropozitivnih po metodi cLIA za anti-HPV 6, anti-HPV 11, anti-HPV 16 oziroma anti-HPV 18, ter 88 %, 81 %, 100 % oziroma 81 % oseb seropozitivnih po metodi IgG LIA za anti-HPV 6, anti-HPV 11, anti-HPV 16 oziroma anti-HPV 18.
Eight-hundred and twenty-three patients (23% women) were randomised to receive 12 weeks of treatment with Ranexa 750 mg twice daily, 1000 mg twice daily, or placebo.
823 bolnikov (23 % žensk) so naključno razdelili tako, da so 12 tednov dvakrat na dan prejemali 750 mg ali 1000 mg zdravila Ranexa ali placebo.
Eighteen cases of overdose have been reported in the literature concerning doses up to 14.4 g.
V literaturi so poročali o osemnajstih primerih prevelikega odmerjanja za odmerke do 14,4 g.
Eighteen of 29 patients (62 %) with parathyroid carcinoma and 15 of 17 subjects (88 %) with primary HPT achieved a reduction in serum calcium of  1 mg/dl ( 0.25 mmol/l).
Osemnajstim od 29 bolnikov (62 %) s paratiroidnim karcinomom in 15 od 17 preiskovancev (88 %) s primarnim hiperparatiroidizmom se je kalcij v serumu znižal za � 10 mg/l (� 0,25 mmol/l).
Eighteen of 29 patients (62%) with parathyroid carcinoma and 15 of 17 subjects (88%) with primary HPT achieved a reduction in serum calcium of ≥ 1 mg/dl (≥ 0.25 mmol/l).
Osemnajstim od 29 bolnikov (62 %) s paratiroidnim karcinomom in 15 od 17 preiskovancev (88%) s primarnim hiperparatiroidizmom se je kalcij v serumu znižal za ≥ 10 mg/l (≥ 0,25 mmol/l).
Eighteen percent of patients achieved, or had an improved response [MR (11%) or PR (7%)] with combination treatment.
Pri 18% bolnikov so dosegli odziv ali izboljšan odziv [MR (11% ali PR (7%)] pri kombiniranem zdravljenju.
Eighty percent (80%) of the subjects had a body mass index (BMI)  27.
Osemdeset odstotkov (80 %) preiskovancev je imelo indeks telesne mase (ITM)  27.
Eighty percent of patients had received prior autologous stem cell transplantation (ASCT).
Osemdesetim odstotkom bolnikov so predhodno opravili avtologno presaditev matičnih celic.
Eighty three percent were white (56% Caucasian/European heritage and 28% Arabic/North African heritage), 11% African American/African, and 6% Asian.
83 % je bilo belcev (56 % kavkaškega/evropskega porekla in 28 % arabskega/severnoafriškega porekla), 11 % je bilo Afroameričanov/Afričanov in 6 % Azijcev.
Eighty-four (84) patients, 39 of whom had received two or more prior induction regimens and 31 whom had received one prior induction regimen, were treated with 650 mg/m2/day of nelarabine administered intravenously over 1 hour daily for 5 consecutive days repeated every
Štiriinosemdeset (84) bolnikov, od katerih jih je 39 predhodno bilo zdravljenih z dvema ali več indukcijskimi režimi zdravljenja, 31 pa z enim indukcijskim režimom zdravljenja, je nelarabin prejemalo v odmerku 650 mg/m2/dan v obliki enourne intravenske infuzije 5 zaporednih dni enkrat dnevno.
Eighty-two percent had M1c stage, 73% had at least two and 32% of patients had three or more prior systemic therapies for advanced melanoma.
Dvainosemdeset odstotkov je imelo M1c stadij, 73 % je imelo predhodno vsaj dve in 32 % je imelo predhodno tri ali več sistemskih zdravljenj za napredovali melanom.
Eimeria acervulina, strain 003 ....................................
Eimeria acervulina, sev 003...........................................332–450
Eimeria acervulina, strain 003 332–450
Eimeria acervulina, sev 003 332–450
Eimeria brunetti, strain 034 213–288
Eimeria brunetti, sev 034 213–288
Eimeria maxima, strain 013 196–265
Eimeria maxima, sev 013 196–265
Eimeria necatrix, strain 033 ........................................
Eimeria necatrix, sev 033...............................................340–460
Eimeria necatrix, strain 033 340–460
Eimeria necatrix, sev 033 340–460
Eimeria tenella, strain 004 ..........................................
Eimeria tenella, sev 004.................................................276–374
Eimeria tenella, strain 004 276–374
Eimeria tenella, sev 004 276–374
Einsteinweg 101
Imunizacija
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom e-mail: EUmedinfo@eisai.net
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija e-pošta: EUmedinfo@eisai.net
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom. e-mail: EUmedinfo@eisai.net
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija. e-pošta: EUmedinfo@eisai.net
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, Velika Britanija
Either Briviact or placebo was added to patients’ usual epilepsy treatment.
Bolniki so poleg svojega običajnega zdravila za epilepsijo prejeli še zdravilo Briviact ali placebo.
Either into a vein or a tube that goes into a vein (intravenously)
bodisi v veno ali cevko, ki gre v veno (intravensko),
Either of which was administered with:
Kapecitabin ali 5-fluorouracil so dajali skupaj s:
either press the hinged section of the safety guard down onto a hard surface or push the hinge forward with your finger
bodisi pritisnite zglob varnostnega ščitnika navzdol ob trdo površino ali pa zglob potisnite naprej s prstom.
Either ritonavir or cobicistat is used with Prezista as a ‘booster’.
Ritonavir ali kobicistat se z zdravilom Prezista uporabljata kot
Either the intact PTH (iPTH) or bio- intact PTH (biPTH) may be used to measure PTH levels; treatment with cinacalcet does not alter the relationship between iPTH and biPTH.
Za merjenje koncentracije PTH je mogoče uporabiti intaktni PTH (iPTH) ali biointaktni PTH (biPTH); zdravljenje s cinakalcetom ne spremeni razmerja med iPTH in biPTH.
eizure
epileptične krče,
eizure (convulsions)
epileptični napadi (krči),
eizure (convulsions),
epileptični napadi (krči),
eizure (fits)
epileptični napadi (krči)
eizure (fits) confusion
konvulzije (napadi krčev), zmedenost.
eizure s (fits or convulsions).
napade krčev (epileptične napade ali konvulzije).
eizure,
epileptični krči,
eizure, fainting or feeling faint, dizziness,
epileptični krči, omedlevica ali občutek, da boste omedleli, omotica,
eizure, impaired consciousness, encephalopathy,
epileptični napad, motnje zavesti, encefalopatija,
eizure; lack of energy; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs
epileptični napad, pomanjkanje energije, vnetje živcev, kar povzroči odrevenelost, šibkost, mravljinčenje ali pekočo bolečino v rokah in nogah
eizures
epileptične napade,
eizures (convulsions or fits)
konvulzije (epileptični napadi),
eizures (convulsions or fits)
konvulzije (napadi krčev),
eizures (convulsions)
napadi (konvulzije)
eizures (convulsions) and bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement),
epileptični napadi (konvulzije) in bipolarne motnje (motnje v razpoloženju z značilnimi izmenjavami žalosti in navdušenja),
eizures (convulsions),
epileptični napadi (konvulzije),
eizures (convulsions),
epileptični napadi (konvulzije).
eizures (epilepsy)
epileptični napadi;
eizures (fits)
epileptični krči
eizures (fits)
krči,
eizures (including febrile seizures)
krči (vključno z vročinskimi krči)
eizures (see section 4.4)
konvulzije (glejte poglavje 4.4.)
eizures or fits bleeding or bruising more easily than normal
epileptični napadi ali krči; krvavitve ali neobičajno hiter pojav modric.
eizures were
epileptične napade11
eizures, usually associated with a history of seizures (epilepsy)
krče, običajno povezane s krči (epileptičnimi napadi) v preteklosti,
Ejaculation delayed (N)
zapoznela ejakulacija (N)
Ejaculation disorder Ejaculation delayed
erektilna disfunkcija motnje ejakulacije zapoznela ejakulacija
Ejaculatory disorders, including retrograde ejaculation, anejaculation
motnje ejakulacije, vključno z retrogradno ejakulacijo, anejakulacijo
Ejection fraction decreased
zmanjšan iztisni delež
Ejection fraction decreased
zmanjšanje iztisnega deleža
Ejection fraction decreased*
zmanjšanje iztisnega deleža
Ejection fraction decreased, Blood bilirubin increased
zmanjšan iztisni delež, zvišanje bilirubina v krvi
Eklira Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair 322 mikrogramov/odmerek prašek za inhaliranje aklidinij (aklidinijev bromid)
Eklira Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair 322 mikrogramov/odmerek prašek za inhaliranje aklidinij (aklidinijev bromid)
Eklira Genuair contains lactose monohydrate
Zdravilo Eklira Genuair vsebuje laktozo monohidrat
Eklira Genuair is a medicine that contains the active substance aclidinium bromide.
Eklira Genuair je zdravilo, ki vsebuje zdravilno učinkovino aklidinijev bromid.
Eklira Genuair is a white or almost white powder.
Zdravilo Eklira Genuair je bel ali skoraj bel prašek.
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Zdravilo Eklira Genuair je indicirano za vzdrževalno bronhodilatacijsko zdravljenje za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Eklira Genuair is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
Zdravilo Eklira Genuair je indicirano za vzdrževalno zdravljenje kronične obstruktivne pljučne bolezni in ga ne smete uporabljati za zdravljenje nenadnega napada zadihanosti ali sopenja.
Eklira Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, long- term lung disease characterised by breathing difficulties.
Zdravilo Eklira Genuair je indicirano za pomoč pri odpiranju dihalnih poti in lajšanju simptomov KOPB, resni, dolgotrajni pljučni bolezni, za katero so značilne dihalne težave.
Eklira Genuair is not for use in children or adolescents below 18 years of age.
Zdravilo Eklira Genuair ni namenjeno za otroke ali mladostnike do 18. leta starosti.
Eklira Genuair is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Zdravilo Eklira Genuair se uporablja za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Eklira Genuair may have minor influence on the ability to drive and use machines.
Zdravilo Eklira Genuair lahko ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Eklira Genuair must not be used in people who are hypersensitive (allergic) to aclidinium bromide, atropine, other related anticholinergic bronchodilator medicines, or any of the other ingredients.
Zdravila Eklira Genuair ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aklidinijev bromid, atropin, druge povezane antiholinergične bronhodilatatorje ali katero koli drugo sestavino zdravila.